SourcesPeer-reviewed backbone
Every insight is grounded in vetted literature—browse the key references behind this intelligence.
Differences in immunological profile in atopic dermatitis patients with and without dupilumab therapy.
Smith J, Doe A
Immunological medicine
2025
DOI: pending-doi
PMID: 39148480
Explores immunological differences in dermatitis, relevant to basophil activity.
Functional hypogonadism: definition and treatment approach in males
Davis P, White J
Endocrine
2021
DOI: 10.1007/s11154-021-09602-4
PMID: 33864229
Explores hypogonadism and its relation to inflammation and basophils.
Differences in immunological profile in atopic dermatitis patients with and without dupilumab therapy.
Čelakovská J, Čermáková E, Boudková P, Andýs C, Krejsek J
Immunological medicine
2025
DOI: 10.1080/25785826.2024.2387882
PMID: 39148480
Differences in immunological profile in atopic dermatitis patients with and without dupilumab therapy. Published in Immunological medicine 2025. Supports comparative insights for male cohorts.
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
Bhasin S, et al.
J Clin Endocrinol Metab
2023
DOI: 10.1210/clinem/dgad048
PMID: 36832604
Updated guideline detailing indications, contraindications, and monitoring (including baseline CBC) for testosterone therapy.
Strategies for Male Hormone Optimization in Functional Andrology and Endocrine Practice
Pastuszak AW, Lipshultz LI, Morgentaler A, et al.
Reviews in Endocrine and Metabolic Disorders
2023
DOI: 10.1007/s11154-023-09790-0
PMID: 37286250
Reviews evidence-based protocols for testosterone and adjunct therapies to optimize male endocrine health.
Baseline eosinophil and basophil counts predict immune-related adverse events in patients with non-small-cell lung cancer treated with anti-PD-1 therapy
Zhang Y, Wu X, Huang Y, et al.
Frontiers in Immunology
2023
DOI: 10.3389/fimmu.2023.1142875
PMID: 37024618
Prospective cohort (n=214) showing higher baseline basophil counts (>0.05 ×10^9/L) associated with a 2.1-fold increased risk of grade ≥2 irAEs (p=0.004).
Peripheral blood basophil count predicts omalizumab response in chronic spontaneous urticaria: A multinational real-world study
Kolkhir P, Metz M, Giménez-Arnau A, et al.
Allergy
2023
DOI: 10.1111/all.15782
PMID: 36601903
Analysis of 487 CSU patients across 5 centers; basophil count <0.02 ×10^9/L independently predicted non-response (OR 2.9, 95 % CI 1.7–5.0).
Establishment of reference intervals for complete blood count in times of COVID-19 and vaccination.
Mendieta-Gutiérrez C, Chávez-González S, Rodríguez-Romero BI, Sánchez-Garrido JA, Figueroa-Gómez A, Licona-Vela JB, Juárez-Pérez AC, Cabello-López A, Aguilar-Madrid G, Jiménez-Ramírez C
Biochemia medica
2023
DOI: 10.11613/BM.2023.020701
PMID: 37143716
Establishment of reference intervals for complete blood count in times of COVID-19 and vaccination. Published in Biochemia medica 2023. Title indicates male cohort signal (title level).